India, June 25 -- Sinovac Biotech Ltd. (SVA) announced that the South African Health Products Regulatory Authority or SAHPRA granted conditional registration to Chinese COVID-19 vaccine CoronaVac. It is administered by intramuscular injection in two doses between 14-28 days apart from the initial dose for individuals 18-59 years of age.
SAHPRA registered CoronaVac with conditions on June 14, 2022. The conditions include that the vaccine is supplied and administered in accordance with South Africa's National Department of Health COVID-19 vaccination plan and applicable guidelines.
SINOVAC stated that its COVID-19 vaccine has been available in more than 60 countries, with a total supply of almost 2.9 billion doses. The CoronaVac(r) was prev...